Recombinant IL17A (Secukinumab Biosimilar) anticorps

N° du produit ABIN7795097

Cet anticorps Humanized Monoclonal détecte spécifiquement IL17A (Secukinumab Biosimilar) dans FACS et in vivo. Il présente une réactivité avec des échantillons de Humain.

Aperçu rapide pour Recombinant IL17A (Secukinumab Biosimilar) anticorps (ABIN7795097)

Antigène: IL17A (Secukinumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Humanized

Clonalité: Monoclonal

Conjugué: Cet anticorp IL17A (Secukinumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Classe de qualité: Research Grade

Détail du produit anti-IL17A (Secukinumab Biosimilar) anticorps

Expression System: Mammalian cells

Fonction: Secukinumab Biosimilar, Human IL17A Monoclonal Antibody

Attributs du produit: What is secukinumab biosimilar research grade? Research grade secukinumab biosimilar uses the same protein sequences as the therapeutic antibody secukinumab. Secukinumab, the humanized anti-IL17A monoclonal antibody, inhibits interleukin 17A, which is a member of the cytokine family, and produced mainly by inflammatory T helper 17 cells. IL17A is upregulated in serum of people with psoriasis and in the synovial fluid of people with psoriatic arthritis, and promotes inflammation when it binds to the interleukin-17 receptor which is expressed in various types of cells, including keratinocytes in skin.

Purification: Protein A or G affinity column

Pureté: >95 % by reducing SDS-PAGE

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method

Immunogène: Human IL17A

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: > 3 mg/mL

Stock: 4 °C,-20 °C

Stockage commentaire: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Détails sur IL17A (Secukinumab Biosimilar)

Antigène: IL17A (Secukinumab Biosimilar)

Autre désignation: Secukinumab Biosimilar

Classe de substances: Biosimilar